by Alex Kadhim
Researchers at University College London and collaborators have determined that matched allogeneic donor CD19 CAR T-cell therapy, delivered as a CAR-modified donor lymphocyte infusion, is safe and...
by Alex Kadhim
Researchers at University Hospital Erlangen and collaborators have observed that CD19 CAR T-cell therapy has a more favorable safety profile in systemic lupus erythematosus (SLE) than in B-cell...
by Alex Kadhim
Researchers from MD Anderson investigated why some follicular lymphoma (FL) patients experience benefit from axicabtagene ciloleucel (axi-cel) while others relapse or develop severe toxicities....
by Alex Kadhim
Researchers from King’s College London and collaborators have investigated how different CAR-T products imprint distinct metabolic programs following infusion in patients with...
by Alex Kadhim
Published in the American Journal of Physical Medicine & Rehabilitation, a brief report explores how cancer patients fare in inpatient rehabilitation after receiving chimeric antigen receptor...
by Alex Kadhim
Researchers at the Children's Hospital of Philadelphia have developed a new strategy to improve the effectiveness of GPC2-directed CAR T-cell therapy in neuroblastoma by reprogramming the...